{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-036855","form_type":"8-K","ticker":"KAPA","cik":"0001962011","company_name":"Kairos Pharma, LTD.","filed_at":"2024-09-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.282551+00:00","generated_at":"2026-05-31T04:23:58.391668+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Kairos Pharma closes $6.2M IPO; shares trade on NYSE American under KAPA","bullets":["Closed IPO of 1,550,000 shares at $4.00/share; gross proceeds $6,200,000.","Underwriters granted 45-day option for additional 232,500 shares at same price.","Proceeds to fund Phase 1 lung cancer and Phase 2 prostate cancer trials for lead candidate ENV 105.","Issued two warrants to underwriters for 54,250 shares each at $4.80 exercise price, exercisable from Mar 2025 to Sep 2029.","Common stock began trading on NYSE American on Sept 16, 2024 under symbol KAPA."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-036855","json":"https://secwatch.observer/filing/0001493152-24-036855.json","markdown":"https://secwatch.observer/filing/0001493152-24-036855.md","text":"https://secwatch.observer/filing/0001493152-24-036855.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1962011/000149315224036855/0001493152-24-036855-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1962011/000149315224036855/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T04:23:58.391668+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}